Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Cboe Europe  -  06:24 2022-10-03 am EDT
763.75 DKK   +0.31%
02:37aA long term support level to be taken advantage of
MS
09/29European ADRs Move Lower in Thursday Trading
MT
09/29Novo Nordisk Enters Exclusive Worldwide License Agreement With Ventus Therapeutics
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

European ADRs Move Higher in Thursday Trading

08/04/2022 | 11:07am EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ADAPTIMMUNE THERAPEUTICS PLC 1.42% 1.075 Delayed Quote.-71.33%
AKARI THERAPEUTICS, PLC 5.00% 0.63 Delayed Quote.-58.00%
AUTOLUS THERAPEUTICS PLC -4.04% 2.14 Delayed Quote.-58.77%
BARCLAYS PLC -0.49% 143.52 Delayed Quote.-22.83%
BICYCLE THERAPEUTICS PLC -2.15% 23.26 Delayed Quote.-61.79%
BRITISH AMERICAN TOBACCO PLC 0.06% 3227 Delayed Quote.18.04%
CELLECTIS S.A. -4.12% 2.328 Real-time Quote.-67.37%
EQUINOR ASA 2.79% 368.25 Real-time Quote.51.80%
ERYTECH PHARMA S.A. 0.89% 0.5655 Real-time Quote.-73.56%
FORWARD PHARMA A/S -4.52% 2.96 Delayed Quote.-50.42%
GRIFOLS, S.A. -3.24% 8.594 Delayed Quote.-47.37%
ING GROEP N.V. -1.73% 8.705 Real-time Quote.-27.64%
LLOYDS BANKING GROUP PLC -0.30% 41.25 Delayed Quote.-13.41%
NOVO NORDISK A/S 0.12% 762.4 Delayed Quote.3.59%
VEON LTD. -4.79% 0.32 Delayed Quote.-81.29%
All news about NOVO NORDISK A/S
09/29European ADRs Move Lower in Thursday Trading
MT
09/29Novo Nordisk Enters Exclusive Worldwide License Agreement With Ventus Therapeutics
MT
09/28European ADRs Move Higher in Wednesday Trading
MT
09/26Novo Nordisk A/S – Share repurchase programme
GL
09/26Novo Nordisk A/S – Share repurchase programme
GL
09/22Novo Nordisk Says Phase 3a Trial of Once-Weekly Insulin Icodec Met Primary Endpoint
MT
09/22Novo Nordisk's Trial Finds Weekly Insulin More Effective Than Daily Insulin Jabs
MT
09/21European ADRs Move Lower in Wednesday Trading
MT
09/21NOVO NORDISK : Deutsche Bank remains its Buy rating
MD
09/20Octagon Therapeutics Enters Inflammation-Focused Research Alliance with Novo Nordisk
CI
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 171 B 22 581 M 22 581 M
Net income 2022 54 527 M 7 185 M 7 185 M
Net cash 2022 1 098 M 145 M 145 M
P/E ratio 2022 31,3x
Yield 2022 1,53%
Capitalization 1 723 B 227 B 227 B
EV / Sales 2022 10,0x
EV / Sales 2023 8,77x
Nbr of Employees 50 816
Free-Float 69,6%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 761,40 DKK
Average target price 836,08 DKK
Spread / Average Target 9,81%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S3.59%227 057
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY17.06%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296